{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-055070","form_type":"8-K","ticker":"TXMD","cik":"0000025743","company_name":"TherapeuticsMD, Inc.","filed_at":"2026-05-12T20:10:33+00:00","discovered_at":"2026-05-12T20:12:00.537372+00:00","generated_at":"2026-05-12T21:00:01.514403+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TherapeuticsMD Q1 2026 net income $103K, license revenue up 84% YoY","bullets":["Net income from continuing operations of $103K vs net loss of $636K in Q1 2025.","License revenue $724K, up 84% YoY, primarily from Mayne License Agreement.","Total operating expenses $1.45M, down 13.6% from $1.67M in prior year.","Cash and cash equivalents $8.4M as of March 31, 2026.","Company continues to evaluate strategic alternatives including M&A or sale of assets."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-055070","json":"https://secwatch.observer/filing/0001213900-26-055070.json","markdown":"https://secwatch.observer/filing/0001213900-26-055070.md","text":"https://secwatch.observer/filing/0001213900-26-055070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/0001213900-26-055070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/25743/000121390026055070/ea0289776-8k_therapeu.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T21:00:01.514403+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}